CONGRESS 2023 - Precision medicine and its impact on health and health delivery
NHS England established the Genomic Medicine Service (GMS) in 2018 to realise the potential of genomics in healthcare. The NHS GMS built upon the existing NHS infrastructure and used learnings from the 100,000 Genomes Project to embed genomics through a world leading innovative service model from primary and community care through to specialist and tertiary care. A consolidated national genomic laboratory network was established with seven GMS Alliances working together to support the clinical leadership and embedding of genomic medicine in end-to-end pathways more broadly and the working with other key clinical specialties. Equitable genomic testing is delivered through a single mandated National Genomic Test Directory for improved outcomes in cancer, rare, inherited and common diseases, and in enabling precision medicine and reducing adverse drug reactions. Working in partnership with Genomics England the delivery of the whole genome sequencing service and ongoing key research initiatives are integral in developing the genomic service. Ongoing evolution of the service through cutting-edge science, research and innovation to ensure that patients can benefit from rapid implementation of advances is critical.
Download as vCalendar (for Microsoft Outlook etc.)
Import event to your Google Calendar
NHS England established the Genomic Medicine Service (GMS) in 2018 to realise the potential of genomics in healthcare. The NHS GMS built upon the existing NHS infrastructure and used learnings from the 100,000 Genomes Project to embed genomics through a world leading innovative service model from primary and community care through to specialist and tertiary care.
A consolidated national genomic laboratory network was established with seven GMS Alliances working together to support the clinical leadership and embedding of genomic medicine in end-to-end pathways more broadly and the working with other key clinical specialties. Equitable genomic testing is delivered through a single mandated National Genomic Test Directory for improved outcomes in cancer, rare, inherited and common diseases, and in enabling precision medicine and reducing adverse drug reactions.
Working in partnership with Genomics England the delivery of the whole genome sequencing service and ongoing key research initiatives are integral in developing the genomic service. Ongoing evolution of the service through cutting-edge science, research and innovation to ensure that patients can benefit from rapid implementation of advances is critical.